The current financial score of vTv Therapeutics Inc is 9.07. Its financial status is robust, and its operating efficiency is high.
The current valuation score of vTv Therapeutics Inc is 8.50. Its current P/E ratio is -63.21, which is -98.72% below the recent high of -0.81 and -190.34% above the recent low of -183.51.
The current earnings forecast score of vTv Therapeutics Inc is 8.40. The average price target is 55.80, with a high of 67.00 and a low of 42.00.
The current price momentum score of vTv Therapeutics Inc is 3.43. Currently, the stock price is trading between the resistance level at 33.64 and the support level at 28.64, making it suitable for range-bound swing trading.
The current institutional shareholding score of vTv Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 35.82%, representing a quarter-over-quarter increase of 19.24%.
The current risk assessment score of vTv Therapeutics Inc is 4.67. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.